Trial Profile
A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Thymosin beta 4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors RegeneRx Biopharmaceuticals
- 22 May 2015 Results published in a RegeneRx Biopharmaceuticals media release.
- 22 May 2015 According to a RegeneRx Biopharmaceuticals media release, data from this study were published in Clinical Ophthalmology.
- 10 Jul 2014 New trial record